4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
88 recruiting
4
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Provectus BioPharmaceuticals, Inc. is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hepatocellular carcinoma | rose bengal disodium | Des.TrialAppr. |
| metastatic melanoma | Rose Bengal Disodium | Des.TrialAppr. |
| neuroblastoma | Rose bengal disodium | Des.TrialAppr. |
| ocular melanoma | rose bengal disodium | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
6
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
6
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio